Details for Patent: 11,819,496

Which drugs does patent 11,819,496 protect, and when does it expire?

Patent 11,819,496 protects ZORYVE and is included in two NDAs.

This patent has forty patent family members in thirteen countries.

Summary for Patent: 11,819,496

Title:	Topical roflumilast formulation having improved delivery and plasma half-life
Abstract:	The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.
Inventor(s):	David W. Osborne
Assignee:	Arcutis Biotherapeutics Inc
Application Number:	US18/176,601
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,819,496
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

United States Patent 11,819,496: Roflumilast Formulation Scope, Patent Strength, and Generic Entry Risk

US Patent No. 11,819,496 protects selected topical roflumilast treatments for psoriasis and inflammatory dermatoses, including atopic dermatitis. Its core limitation is not roflumilast alone. The claims require a formulation containing roflumilast, diethylene glycol monoethyl ether, and a specific emulsifier blend of cetostearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate. The claims also require a roflumilast plasma half-life of approximately three to five days. Claims 18-20 add once-daily dosing and persistence of therapeutic levels after a missed dose.

The patent is commercially relevant to Zoryve, Arcutis Biotherapeutics' topical roflumilast products. Its practical strength depends on whether a generic formulation uses the claimed emulsifier system and whether the claimed pharmacokinetic result can be established for the generic product.

What does US Patent 11,819,496 cover?

The patent covers method-of-treatment claims directed to topical formulations of roflumilast. It does not claim every topical roflumilast formulation.

Claim group	Disease or use	Required formulation features	Additional limitations
Claim 1	Psoriasis	Roflumilast, diethylene glycol monoethyl ether, and specified emulsifier blend	Plasma half-life of about 3-5 days
Claims 2-8	Psoriasis	Same core formulation	Concentration, cream or foam, 10% emulsifier blend, 25% solvent
Claim 9	Inflammatory dermatoses	Same core formulation	Plasma half-life of about 3-5 days
Claims 10-17	Inflammatory dermatoses	Same core formulation	0.05%-1% roflumilast, cream or foam, atopic dermatitis
Claim 18	Inflammatory dermatoses	Same core formulation	Once-daily administration and therapeutic level after a missed dose
Claims 19-20	Inflammatory dermatoses	Same core formulation	Cream or foam; 10% emulsifier blend and 25% solvent

The independent claims are claims 1, 9, and 18. Claims 2-8, 10-17, 19, and 20 depend on those broader claims and add formulation, disease, dosage-form, concentration, or dosing limitations (U.S. Patent No. 11,819,496, 2023).

What formulation ingredients are protected by Patent 11,819,496?

The central composition limitation requires all of the following:

1. Roflumilast.
2. Diethylene glycol monoethyl ether, commonly used as a penetration-enhancing solvent.
3. An emulsifier blend comprising:
   • Cetostearyl alcohol;
   • Dicetyl phosphate; and
   • Ceteth-10 phosphate.
4. A quantity of the emulsifier blend sufficient to increase roflumilast plasma half-life.
5. A resulting plasma half-life of about three to five days.

The claim language does not require a specific commercial brand name, container, preservative system, oil phase, water phase, propellant, or manufacturing process. It can therefore reach formulations with materially different excipients if the accused product retains the required ingredients and pharmacokinetic properties.

The claims also do not require every formulation to contain exactly 10% emulsifier blend and 25% diethylene glycol monoethyl ether. Those amounts appear in dependent claims 5-8, 14, 16, 17, and 20. A product outside those amounts could still fall within claims 1, 9, or 18 if it satisfies the broader limitations.

How broad are the psoriasis claims?

Claim 1 is directed to topical treatment of psoriasis. It covers a patient with psoriasis receiving a formulation containing the specified roflumilast system and producing the claimed half-life.

Claim 2 narrows the roflumilast concentration to 0.1%-0.5% by weight. Claim 3 limits the dosage form to a cream or foam. Claims 5-8 identify a formulation with approximately 10% emulsifier blend and 25% diethylene glycol monoethyl ether.

Claim 7 is the most formulation-specific psoriasis claim for a cream:

Parameter	Claim 7 limitation
Active ingredient	Roflumilast
Roflumilast concentration	0.1%-0.5% w/w
Solvent	Approximately 25% w/w diethylene glycol monoethyl ether
Emulsifier blend	Approximately 10% w/w
Dosage form	Cream
Disease	Psoriasis
Pharmacokinetic requirement	Plasma half-life of approximately 3-5 days

Claim 8 applies substantially the same formulation parameters to a foam.

A generic cream containing 0.3% roflumilast could fall within claim 7 if it also uses the claimed emulsifier blend at approximately 10%, includes approximately 25% diethylene glycol monoethyl ether, and meets the half-life limitation. A 0.3% roflumilast product using a different emulsifier system would have a stronger noninfringement position against the dependent claims, although claims 1 or 9 would still require analysis.

How broad are the inflammatory dermatoses and atopic dermatitis claims?

Claims 9-20 extend the patent beyond psoriasis. “Inflammatory dermatoses” is a broader disease category that includes atopic dermatitis and may include other inflammatory skin conditions, depending on the patent specification and claim construction.

Claim 15 expressly identifies atopic dermatitis. Claim 16 then requires:

• 0.05%-1% roflumilast;
• 10% emulsifier blend;
• 25% diethylene glycol monoethyl ether; and
• a cream formulation.

The broader concentration range in claims 10 and 16 is important. It reaches formulations below the 0.1% concentration specified in the psoriasis claims. This potentially covers low-strength topical products developed for sensitive skin, pediatric use, or mild inflammatory dermatoses.

The disease limitation may create a litigation issue. A product label for atopic dermatitis would directly implicate claims 15 and 16. A product labeled only for another dermatosis could still raise inducement concerns if the manufacturer promotes use for a claimed condition or if the product labeling instructs such use.

What is the significance of the plasma half-life limitation?

The half-life limitation is the patent's principal technical and litigation vulnerability.

The independent claims require a plasma half-life of about three to five days, while claims 4 and 12 narrow the range to about three to four days. The claims also state that the emulsifier blend must be present in an amount sufficient to increase roflumilast plasma half-life.

This creates several issues:

• The half-life is a product-performance limitation embedded in a method claim.
• Infringement may require pharmacokinetic evidence rather than ingredient matching alone.
• The measurement protocol, patient population, dosing schedule, and statistical treatment may affect the result.
• The term “about” expands the numerical range but creates claim-construction questions.
• A generic sponsor may argue that its formulation does not produce the claimed systemic exposure or half-life.
• The patent holder may argue that the pharmacokinetic result is an inherent property of a formulation containing the required excipient system.

Claims 18-20 add a second pharmacokinetic or pharmacodynamic limitation: roflumilast must remain at a therapeutically effective level after a patient misses one dose. That limitation may be difficult to prove directly in a commercial infringement case because it requires defining both “therapeutically effective level” and the clinical relevance of a missed dose.

What concentrations and dosage forms are covered?

The patent covers creams and foams through dependent claims, but the independent claims do not expressly require either dosage form. A topical gel, ointment, lotion, solution, or other dosage form could theoretically fall within an independent claim if it satisfies the ingredient and pharmacokinetic limitations.

Product characteristic	Coverage under the claims
Roflumilast 0.3% cream	Potentially within claims 1, 2, 3, 5, 7 and related claims
Roflumilast 0.3% foam	Potentially within claims 1, 2, 3, 5, 8 and related claims
Roflumilast 0.05% cream	Potentially within claims 9, 10, 11, 13, 14, 15, 16 and related claims
Roflumilast 0.05% foam	Potentially within claims 9-15 and 17, depending on exact formulation
Formulation with a different emulsifier	Stronger noninfringement position, subject to equivalents
Formulation without diethylene glycol monoethyl ether	Stronger noninfringement position
Once-daily product	Potentially within claims 18-20
Twice-daily product	May avoid the express once-daily limitation of claim 18, but not necessarily claims 1 or 9

When does Patent 11,819,496 expire?

US Patent 11,819,496 issued on December 26, 2023. Its enforceable term is determined by the earliest applicable nonprovisional or international filing date, plus any patent-term adjustment. The patent appears to belong to a later-generation roflumilast formulation family with an expected statutory term extending into approximately 2037-2038, subject to the official patent-term calculation.

The legally controlling date is the USPTO term calculation, not the grant date. Patent-term adjustment, terminal disclaimers, priority claims, and any patent-term extension could affect the effective expiration date. The patent should therefore be treated as a long-dated barrier relative to the 2022 FDA approval of Zoryve cream and the later approvals of Zoryve foam.

What is the FDA and Orange Book relevance of Patent 11,819,496?

Zoryve is the principal FDA-approved topical roflumilast product associated with this patent estate. FDA approved:

FDA milestone	Product
July 29, 2022	Zoryve cream 0.3% for plaque psoriasis in adults and pediatric patients aged 12 years and older
December 14, 2023	Zoryve foam 0.3% for seborrheic dermatitis in adults and pediatric patients aged 9 years and older
July 9, 2024	Zoryve cream 0.15% for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 6 years and older
July 2024	Zoryve foam 0.3% for atopic dermatitis in adults and pediatric patients aged 6 years and older

The FDA Orange Book lists patents and use codes supplied for approved drug products. A method-of-use patent can create a Paragraph IV issue when its claims cover an FDA-approved indication or dosing method. The commercial effect depends on whether Patent 11,819,496 is listed against the relevant Zoryve NDA and whether the listed use code corresponds to the proposed generic label (FDA, 2024a; FDA, 2024b).

The patent's claims are particularly relevant to approved topical products because they target the same active ingredient, topical route, cream or foam formats, concentrations, and dermatologic indications used by Zoryve. The scope is not limited to a particular brand label, but Orange Book enforcement depends on the precise NDA listing and use code.

How does Patent 11,819,496 compare with the broader Zoryve patent estate?

Patent 11,819,496 appears to be a formulation and pharmacokinetic layer in a larger Zoryve estate. The estate includes earlier patents directed to topical roflumilast compositions, formulations, treatment methods, and dosage forms.

Patent layer	Typical protected subject matter	Generic relevance
Active ingredient patents	Roflumilast molecule	Likely expired or less relevant because roflumilast is an established active ingredient
Formulation patents	Vehicle, solvent, emulsifier, stability, delivery	High relevance to ANDA formulation design
Method-of-use patents	Psoriasis, seborrheic dermatitis, atopic dermatitis, inflammatory dermatoses	Relevant to labeling and Paragraph IV strategy
Pharmacokinetic claims	Plasma half-life and missed-dose persistence	Creates proof and claim-construction issues
Product-specific patents	Cream, foam, concentration, packaging, administration	Can delay or complicate generic substitution

Patent 11,819,496 is narrower than a patent claiming all topical roflumilast compositions, but it may be commercially strong because its limitations align with the product architecture of approved Zoryve products.

Which companies are challenging Zoryve patents?

Publicly reported generic activity should be evaluated through ANDA litigation filings, FDA tentative approvals, and Paragraph IV notices. No widely reported final district-court judgment or settlement involving Patent 11,819,496 is identified in the supplied record.

The absence of a reported judgment does not establish that no Paragraph IV notice has been served. Generic challenges can remain confidential until the reference-listed drug holder files suit. A first-filer challenge would be strategically important because a timely patent suit generally triggers a 30-month FDA approval stay under the Hatch-Waxman framework (21 U.S.C. § 355(j)(5)(B)(iii)).

Likely generic attack routes include:

1. Noninfringement based on a different emulsifier system.
2. Noninfringement based on omitting diethylene glycol monoethyl ether.
3. Failure to meet the three-to-five-day plasma half-life limitation.
4. Invalidity for lack of written description or enablement of the broad inflammatory-dermatoses claims.
5. Obviousness based on known topical roflumilast formulations and conventional emulsifier systems.
6. Indefiniteness arguments directed to “about,” “sufficient to increase,” and “therapeutically effective level.”
7. Labeling strategies that carve out patented indications or once-daily instructions.

How strong is the patent estate for generic launch purposes?

Patent 11,819,496 is moderately strong against a copycat formulation and weaker against a deliberately redesigned formulation.

Risk factor	Assessment
Ingredient overlap	High if the generic copies the solvent and emulsifier system
Concentration overlap	High for 0.3% products and potentially broad for 0.05%-1% products
Dosage-form overlap	High for cream and foam products
Pharmacokinetic proof	Mixed; supports patent holder if inherent, complicates litigation if variable
Disease-method overlap	High for psoriasis and atopic dermatitis labels
Design-around potential	Meaningful through excipient substitution
Biosimilar exposure	None; roflumilast is a small molecule subject to the ANDA pathway
Manufacturing barrier	Limited for ordinary topical manufacture; formulation know-how remains relevant
Litigation leverage	Stronger where the proposed product mirrors Zoryve composition and label

The strongest claims are likely the narrower claims that combine the named emulsifier blend, 10% concentration, 25% diethylene glycol monoethyl ether, and cream or foam dosage form. Those claims provide clear product-comparison points.

The broadest claims, particularly claims 1 and 9, have greater theoretical reach but also present more substantial validity and proof questions. Their breadth comes from covering treatment methods across a disease category and from using a pharmacokinetic result rather than a tightly defined formulation recipe.

What generic launch scenarios exist?

Scenario 1: Copy formulation and full-label launch

A generic sponsor copies the core vehicle, seeks approval for overlapping indications, and receives a Paragraph IV certification. This scenario creates the highest infringement risk and the strongest basis for immediate patent litigation.

Scenario 2: Formulation design-around

The sponsor uses a different emulsifier system or replaces diethylene glycol monoethyl ether. This may avoid literal infringement, but the patent holder could assert equivalents if the substituted components perform substantially the same function in substantially the same way.

Scenario 3: Skinny-label launch

The sponsor removes patented indications or dosing instructions from its label. This approach may reduce method-of-use risk but can be difficult where the FDA-approved use, dosage form, and product labeling overlap with the patent claims.

Scenario 4: Pharmacokinetic challenge

The sponsor accepts the same broad excipient architecture but argues that its product does not produce a three-to-five-day plasma half-life or does not maintain therapeutic levels after a missed dose. This strategy shifts the dispute toward clinical pharmacology and claim construction.

What licensing deals affect the patent estate?

Dermavant Sciences developed and commercialized Zoryve before transferring the business to Arcutis. Arcutis announced an acquisition of Dermavant's assets in 2024, including Zoryve and associated intellectual property. The transaction moved commercial control of the product and related patent rights to Arcutis (Arcutis Biotherapeutics, 2024).

The transfer is commercially significant because patent enforcement, Orange Book maintenance, licensing, and generic settlement negotiations are generally controlled by the current NDA holder and patent owner or their authorized affiliates. Earlier development, prosecution, and licensing agreements may still affect ownership or enforcement rights, but the principal commercial counterparty is Arcutis.

Does the patent create biosimilar risk?

No. Roflumilast is a small-molecule active pharmaceutical ingredient. Competitive products would generally proceed through the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act.

The relevant risks are:

• ANDA Paragraph IV challenges;
• Paragraph III certifications with delayed launch;
• Skinny-label approval;
• Formulation design-around;
• Authorized generic or licensing arrangements; and
• OTC or prescription-market substitution depending on future FDA approvals.

What revenue exposure does the patent protect?

Zoryve revenue is exposed to generic entry across several commercial segments:

Segment	Patent relevance
Psoriasis cream 0.3%	Direct overlap with claims 1-8
Seborrheic dermatitis foam 0.3%	Potential overlap with inflammatory-dermatoses method claims, depending on claim construction and listing
Atopic dermatitis cream 0.15%	Direct relevance to claims 9-16
Atopic dermatitis foam 0.3%	Direct relevance to claims 9-11 and 17-20
Future roflumilast topical indications	Potentially covered if the formulation and half-life limitations remain satisfied

The patent is more valuable for product-line protection than for protection of roflumilast as a molecule. A successful generic design-around could preserve active-ingredient competition while avoiding this particular patent.

Key Takeaways

• Patent 11,819,496 is a method patent covering topical roflumilast formulations for psoriasis and inflammatory dermatoses.
• The required formulation contains roflumilast, diethylene glycol monoethyl ether, and a specific emulsifier blend of cetostearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate.
• The core claims require a plasma half-life of approximately three to five days.
• Claims 18-20 add once-daily dosing and therapeutic persistence after a missed dose.
• The patent is highly relevant to Zoryve cream and foam products, including psoriasis and atopic dermatitis products.
• The strongest infringement case would involve a generic that copies the named excipients, 10% emulsifier blend, 25% solvent, cream or foam format, and overlapping indication.
• The most credible design-around strategy is excipient substitution, particularly replacement of the specified emulsifier blend or diethylene glycol monoethyl ether.
• The principal validity pressure points are obviousness, written description, enablement, indefiniteness, and the evidentiary basis for the half-life and missed-dose limitations.
• Roflumilast has generic, not biosimilar, competition risk.
• Arcutis became the principal commercial owner of the Zoryve business and associated intellectual property after acquiring Dermavant assets in 2024.

FAQs About US Patent 11,819,496

Does Patent 11,819,496 cover all roflumilast creams?

No. It requires the claimed solvent, emulsifier blend, and pharmacokinetic result. A roflumilast cream using materially different excipients may avoid literal infringement.

Does the patent cover roflumilast foam?

Yes, dependent claims expressly recite a cream or foam, including claims 3, 8, 11, 17, and 19. The formulation and plasma half-life limitations still apply.

Can a generic launch before the patent expires?

Potentially, through a successful Paragraph IV challenge, a noninfringing formulation, a skinny-label strategy, a settlement, or a license. A copycat product faces greater launch risk.

Is the three-to-five-day half-life limitation easy to enforce?

No. Enforcement would likely require validated pharmacokinetic evidence and agreement on the meaning of “about,” the relevant patient population, and the testing conditions.

Is Patent 11,819,496 the only patent protecting Zoryve?

No. Zoryve is protected by a broader patent estate that includes formulation, dosage-form, treatment-method, and product-specific rights. A generic must evaluate the full estate rather than this patent alone.

References

Arcutis Biotherapeutics, Inc. (2024). Arcutis announces acquisition of Dermavant assets, including Zoryve. Company press release.

U.S. Food and Drug Administration. (2024a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (2024b). Zoryve prescribing information and approval materials. https://www.accessdata.fda.gov/

U.S. Patent No. 11,819,496. (2023). Methods of treating psoriasis and inflammatory dermatoses with topical roflumilast compositions. United States Patent and Trademark Office.

U.S. Code, 21 U.S.C. § 355(j)(5)(B)(iii). Abbreviated new drug applications and patent certifications.

Drugs Protected by US Patent 11,819,496

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-002	Jul 9, 2024		RX	Yes	Yes	11,819,496					TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-001	Jul 29, 2022		RX	Yes	Yes	11,819,496					TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE AND OLDER
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-001	Jul 29, 2022		RX	Yes	Yes	11,819,496					TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 2 YEARS OF AGE OR OLDER
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-003	Oct 4, 2025		RX	Yes	Yes	11,819,496					TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 2 TO 5 YEARS OF AGE

International Family Members for US Patent 11,819,496

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018282098
Australia	2021214399
Brazil	112019025748
Brazil	112022015104